Lack of skin carcinogenicity of topically applied titanium dioxide nanoparticles in the mouse

Food and Chemical Toxicology

Volumn 49, Issue 4, 2011, Pages 744-749

  Furukawa, Fumio ^a   Doi, Yuko ^a   Suguro, Mayuko ^a   Morita, Osamu ^b   Kuwahara, Hirofumi ^c,g   Masunaga, Takuji ^d,g   Hatakeyama, Yoshiro ^e,g   Mori, Fukuyoshi ^f  

^a Daiyukai Research Institute for Medical Science   (Japan)

^b KAO CORPORATION   (Japan)

^c Kanebo Cosmetics Inc   (Japan)

^d Cutaneous Research Section   (Japan)

^e SHISEIDO RESEARCH CENTER   (Japan)

^f POLA CHEMICAL INDUSTRIES INC   (Japan)

^g Japan Cosmetic Industry Association   (Japan)

Author keywords

Cosmetics; Nanomaterial; Skin carcinogenicity; Titanium dioxide; Two stage model

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; PHORBOL 13 ACETATE 12 MYRISTATE; TITANIUM DIOXIDE; TITANIUM DIOXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HYPERPLASIA; INGUINOFEMORAL LYMPH NODE; KERATOACANTHOMA; LUMBAR LYMPH NODE; LYMPH NODE; MANDIBULAR LYMPH NODE; MOUSE; NONHUMAN; PANCREATIC LYMPH NODE; PAPILLOMA; SEBACEOUS GLAND; SKIN CARCINOGENESIS; SKIN NODULE; SPLEEN; SQUAMOUS CELL; SURVIVAL RATE; THYMUS;

MUS;

EID: 79952451704     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2010.11.036     Document Type: Article

References (17)

1. Ashby J., Tennant R.W. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat. Res. 1991, 257:229-306.
2. Berenblum I. The carcinogenic action of croton resin. Cancer Res. 1941, 1:44-48.
3. Borm P.J., Robbins D., Haubold S., Kuhlbusch T., Fissan H., Donaldson K., Schins R., Stone V., Kreyling W., Lademann J., Krutmann J., Warheit D., Oberdorster E. The potential risks of nanomaterials: a review carried out for ECETOC. Part. Fibre Toxicol. 2006, 3:1-35.
4. Gamer A.O., Leibold E., van Ravenzwaay B. The in vitro absorption of microfine zinc oxide and titanium dioxide through porcine skin. Toxicol. In vitro 2006, 20:301-307.
5. Gopee N.V., Cui Y., Olson G., Warbritton A.R., Miller B.J., Couch L.H., Wamer W.G., Howard P.C. Response of mouse skin to tattooing: use of SKH-1 mice as a surrogate model for human tattooing. Toxicol. Appl. Pharmacol. 2005, 209:145-158.
6. IARC monographs on the evaluation of carcinogenic risks to humans, 2006. Carbon Black, Titanium Dioxide and Non-Asbestiform Talc.
7. Kiss B., Bíró T., Czifra G., Tóth B.I., Kertész Z., Szikszai Z., Kiss A.Z., Juhász I., Zouboulis C.C., Hunyadi J. Investigation of micronized titanium dioxide penetration in human skin xenografts and its effect on cellular functions of human skin-derived cells. Exp. Dermatol. 2008, 17:659-667.
8. Lademann J., Weigmann H., Rickmeyer C., Barthelmes H., Schaefer H., Mueller G., Sterry W. Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol. Physiol. 1999, 12:247-256.
9. National Cancer Institute, Carcinogenesis, Technical Report Series No.97, 1979. Bioassay of titanium dioxide for possible carcinogenicity (CAS No. 3463-67-7) NCI-CG-TR-97. Available from: http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr097.pdf.
10. Rouse J.G., Yang J., Ryman-Rasmussen J.P., Barron A.R., Monteiro-Riviere N.A. Effects of mechanical flexion on the penetration of fullerene amino acid-derivatized peptide nanoparticles through skin. Nano Lett. 2007, 7:155-160.
11. Sato H., Toyoda K., Furukawa F., Okamiya H., Shimoji N., Hasegawa R., Takahashi M., Hayashi Y. Effects of 9 mutageic pyrolysates, 5 foodstuffs, 4 anti-tumor drugs and 6 heavy metals in a two-stage mouse skin model. J. Toxicol. Pathol. 1988, 1:39-45. (in Japanese).
12. Scientific Committee on Consumer Products (SCCP), 2007. SCCP/1147/07: Opinion on safety of nanomaterial in cosmetic products. Adopted by the SCCP after the public consultation on the 14th plenary of 18 December 2007.
13. Shelby M.D. The genetic toxicity of human carcinogens and its implications. Mutat. Res. 1988, 204:3-15.
14. Shelby M.D., Zeiger E. Activity of human carcinogens in the salmonella and rodent bone-marrow cytogenetics tests. Mutat. Res. 1990, 234:257-261.
15. Tanaka H., Takesada Y., Shibata M.A., Kawabe M., Sano M., Tamano S., Sugimoto H., Nakamura T., Hagiwara A. Lack of tumor promoting effects of KCB-1, a recombinant human basic fibroblast growth factor, on two-stage skin carcinogenesis in female CD-1 (ICR) mice. Cancer Lett. 1996, 105:195-202.
16. Tinkle S.S., Antonini J.M., Rich B.A., Roberts J.R., Salmen R., DePree K., Adkins E.J. Skin as a route of exposure and sensitization in chronic beryllium disease. Environ. Health Perspect. 2003, 111:1202-1208.
17. Witt K.L., Knapton A., Wehr C.M., Hook G.J., Mirsalis J., Shelby M.D., MacGregor J.T. Micronucleated erythrocyte frequency in peripheral blood of B6C3F1 mice from short-term, prechronic, and chronic studies of the NTP carcinogenesis bioassay program. Environ. Mol. Mutagen. 2000, 36:163-194.